Sigyn Therapeutics (SIGY) Assets Average (2018 - 2025)
Sigyn Therapeutics (SIGY) posted Assets Average of $93665.0 for Q3 2025, down 36.73% sequentially from $148034.0 in Q2 2025, and down 74.94% YoY from $373801.5 in Q3 2024.
Sigyn Therapeutics (SIGY) Assets Average (2018 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Assets Average for 8 years, with the latest figure at $93665.0 in Q3 2025.
- Quarterly Assets Average fell 74.94% year-over-year to $93665.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $93665.0 (down 74.94% YoY) and the FY2024 annual result came in at $267762.5, down 18.2% from the prior year.
- Assets Average declined to $93665.0 in Q3 2025 per SIGY's latest filing, from $148034.0 in the prior quarter.
- Over five years, Assets Average peaked at $1.7 million in Q3 2021 and troughed at $93665.0 in Q3 2025.
- A 5-year average of $527256.8 and a median of $374520.0 in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2022: Assets Average surged 178.49% in 2021, then slumped 77.92% in 2022.
- Over 5 years, Assets Average stood at $1.1 million in 2021, then sank by 67.68% to $347576.0 in 2022, then climbed by 2.0% to $354514.5 in 2023, then fell by 9.57% to $320578.5 in 2024, then plunged by 70.78% to $93665.0 in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $93665.0, $148034.0, and $229014.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 93,665.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 93,665.00 |
| Jun 30, 2025 | 148,034.00 |
| Mar 31, 2025 | 229,014.00 |
| Dec 31, 2024 | 320,578.50 |
| Sep 30, 2024 | 373,801.50 |
| Jun 30, 2024 | 321,730.00 |
| Mar 31, 2024 | 322,550.50 |
| Dec 31, 2023 | 354,514.50 |
| Sep 30, 2023 | 374,520.00 |
| Jun 30, 2023 | 511,132.00 |
| Mar 31, 2023 | 496,663.00 |
| Dec 31, 2022 | 347,576.00 |
| Sep 30, 2022 | 379,090.50 |
| Jun 30, 2022 | 421,661.00 |
| Mar 31, 2022 | 578,836.50 |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.72 Mn |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 651,521.00 |
| Dec 31, 2020 | 652,131.50 |